Literature DB >> 10380906

Identification of CD137 as a potent monocyte survival factor.

J Langstein1, H Schwarz.   

Abstract

CD137 (ILA/4-1BB), a member of the tumor necrosis factor (TNF) receptor family, promotes adherence and prolongs survival of human peripheral monocytes. It induces a strong expression of macrophage colony-stimulating factor (M-CSF), an essential monocyte survival factor. Monocyte survival induced by CD137 is primarily mediated by M-CSF and to a lesser extent by granulocyte-macrophage colony-stimulating factor and IL-3. Survival and induction of M-CSF are mediated via reverse signaling through a CD137 ligand expressed constitutively by peripheral monocytes.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10380906     DOI： 10.1002/jlb.65.6.829

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN： 0741-5400            Impact factor:   4.962


  21 in total

1.  Regulation of mouse 4-1BB expression: multiple promoter usages and a splice variant.

Authors:  Jung D Kim; Chang H Kim; Byoung S Kwon
Journal:  Mol Cells       Date:  2011-01-11       Impact factor: 5.034

2.  CD137 ligand-mediated reverse signaling inhibits proliferation and induces apoptosis in non-small cell lung cancer.

Authors:  Yingying Qian; Dong Pei; Ting Cheng; Changling Wu; Xiaolin Pu; Xiaofeng Chen; Yiqian Liu; Hong Shen; Weiwei Zhang; Yongqian Shu
Journal:  Med Oncol       Date:  2015-01-29       Impact factor: 3.064

Review 3.  CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.

Authors:  Bhushan Dharmadhikari; Meihui Wu; Nur Sharalyn Abdullah; Sakthi Rajendran; Nur Diana Ishak; Emily Nickles; Zulkarnain Harfuddin; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

4.  GeneChip analyses of global transcriptional responses of murine macrophages to the lethal toxin of Bacillus anthracis.

Authors:  Jason E Comer; Cristi L Galindo; Ashok K Chopra; Johnny W Peterson
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

5.  CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses.

Authors:  Zulkarnain Harfuddin; Shaqireen Kwajah; Adrian Chong Nyi Sim; Paul Anthony Macary; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2013-11-11       Impact factor: 8.110

Review 6.  Therapeutic vaccination with tumor cells that engage CD137.

Authors:  Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  J Mol Med (Berl)       Date:  2003-02-08       Impact factor: 4.599

7.  Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling.

Authors:  Charles Gullo; Liang Kai Koh; Wan Lu Pang; Kian Tong Ho; Shi Hao Tan; Herbert Schwarz
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

Review 8.  Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.

Authors:  Robert S Mittler; Juergen Foell; Megan McCausland; Simona Strahotin; Liguo Niu; Abhijit Bapat; L Becker Hewes
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

9.  Recombinant CD137-Fc, its synthesis, and applications for improving the immune system functions, such as tumor immunotherapy and to reduce the inflammation due to the novel coronavirus.

Authors:  Maryam Ajami; Mahboobeh Nazari; Habibollah Mahmoodzadeh; Seyed Mohammad Moazzeni
Journal:  J Cell Biochem       Date:  2021-05-16       Impact factor: 4.429

10.  CD137 ligand activated microglia induces oligodendrocyte apoptosis via reactive oxygen species.

Authors:  Yee Andy Yeo; Julia M Martínez Gómez; J Ludovic Croxford; Stephan Gasser; Eng-Ang Ling; Herbert Schwarz
Journal:  J Neuroinflammation       Date:  2012-07-16       Impact factor: 8.322
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.